Amorepacific Corporation

Miyoung Park

Byoung Young Woo

Joonho Choi

Wonkyung Cho

Jaehong Park

Youngho Park

Kwanghyun Shin

Jong Hwa Roh

Eunsil Park

Kyoungmi Jung

Kiwha Lee

Gyeyoung Choi

Si Young Cho

Juewon Kim

Chang Soon Choi

Hyunjin Nam

Jihae Lee

Jin Sung Kim

Young-Ho Park

Min Soo Kim

Ki-Wha Lee

Wonseok Park

Jaewon You

Hyungsu Kim

Wanki Kim

Sun-Young Kim

Jin Kyu Choi

Yong Deog Hong

Song Seok Shin

Hyun Woo Jeong

Hyun Ju Koh

Shin Chung

Jinoh Chung

Joo-Hyun Moh

Jung Sun Hwang

Kwang-Hyun Shin

Yeonjoon Kim

Sa-Yong Hong

Sung Il Kim

Kyoung Min Lim

Eun Sol Ha

Sarva Jayaprakash

Sridhar Regati

Mamidi Srinivas

Krushnakant Patel

M Ramamohan

Shin Shinchang Missionhill Chung

Song Seok Sk Apt 102-2003 Shin

Kyoung Min Byeokjeoggol Lim

Byoung Young Chamsolmaeul World Meridian Woo

Joo-Hyun Amorepacific Moh

The present disclosure relates to a composition for reducing body fat, which contains a green tea extract containing 4 wt % or more of gallocatechin gallate based on the total weight of the extract as an active ingredient, and a method for preparing the same. The composition according to the present disclosure provides a superior effect of reducing body fat as the green tea extract containing gallocatechin gallate is contained as an active ingredient. Accordingly, it can provide substances effective for treating obesity through various researches.

Composition for reducing body fat comprising green tea extract containing gallocatechin gallate as an active ingredient and manufacturing method thereof

Disclosed is to provide a composition for skin-whitening or preventing or improving skin wrinkles, comprising a green tea extract which has modified amounts of ingredients. More specifically, the extract and composition according to one aspect of the present disclosure are derived from natural plants that cause less irritation to the skin and are eco-friendly, thus they are safe, and thereby the extract and composition can exhibit excellent effects of effectively inhibiting melanin production and tyrosinase activity and preventing or improving skin whitening, and can exhibit excellent effects of effectively inhibiting the expression of MMP-1 and preventing or improving skin wrinkles.

Composition for skin-whitening or preventing or improving skin wrinkles comprising green tea extract which has modified amounts of ingredients

One aspect of the present disclosure relates to a pharmaceutical composition, containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first ingredient and containing a vinylpyrrolidone-based polymer as a second ingredient. The composition of one aspect of the present disclosure has a formulation characteristic in which the crystal formation of a compound represented by chemical formula 1 is delayed for a long time.

Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethylpyridin-3-yl)-acrylamide and method for inhibiting crystal formation thereof

One aspect of the present disclosure relates to a sol-gel composition enabling reversible sol-gel transition and, more specifically, to a sol-gel composition of which the viscosity changes by external physical force so that reversible sol-gel transition is performed.

Topical sol-gel composition for the treatment of dermatitis

An aspect of the present disclosure relates to a composition for improving respiratory health exposed to particulate matter, which contains a green tea extract, a green tea polysaccharide and a green tea flavonol as active ingredients. The composition provided in an aspect of the present disclosure can improve respiratory health damaged by exposure to particulate matter by enhancing the effect of preventing adsorption of particulate matter to bronchial epithelial cells and activating the cilia of bronchial epithelial cells. The composition provided in an aspect of the present disclosure may decrease blood heavy metal level.

Composition for improving respiratory health continuously exposed to particulate matter atmosphere

Disclosed is a method for preventing or treating atopic dermatitis using TRPV1 receptor antagonist. More specifically, it may be possible to prevent and/or treat the atopic dermatitis without any side effects such as an increase in body temperature, epidermal atrophy, and the like by percutaneously administrating a composition for external use on the skin containing the TRPV1 receptor antagonist.

Composition for preventing or treating atopic dermatitis

Disclosed is a method for preventing or treating sleep disorders using TRPV1 receptor antagonist, (R)&#x2014;N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide. The method of the present invention can effectively and safely prevent or treat sleep disorders accompanying pruritus caused by atopic dermatitis.

Composition for preventing or treating sleep disorders

Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ellman-chiral auxiliaries and the recrystallization and separation of optical isomers. According to the above method, high-purity N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide with excellent quality can be produced at room temperature by improving cryogenic process conditions necessary for realizing high optical purity, and thus the trimming due to the process failure rate can be remarkably reduced.

Method for preparing (R)-N-[4-(1-amino-ethyl)-2,6-difluoro-phenyl]-methanesulfonamide

The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxiliary and salt-forming auxiliary compound, wherein the chiral auxiliary is an O,O'-diacyltartaric acid derivative, more specifically, a 2,3-dibenzoyl-tartaric acid or O,O&#x2032;-di-p-toluoyl tartaric acid, the salt-forming auxiliary compound is mandelic acid or camphorsulfonic acid, and an optical isomer having a high level of optical purity can be obtained by using the method. Therefore, according to one aspect of the present invention, the method can be useful in pharmaceutical or cosmetic field when preparing an optical isomer having a high optical purity.

Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives

2-cyclopenten-1-one oxime derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof inhibit the production of TNF-&#x3b1; or PDE4, and therefore show therapeutic effect in inflammatory or immunological disorders mediated through TNF-&#x3b1; or PDE4.

2-cyclopenten-1-one oxime derivatives inhibiting production of TNF-&#x3b1;

Growing community of inventors

Yongin-si, South Korea

Miyoung Park